Bevacizumab and postoperative wound complications in patients with liver metastases of colorectal cancer.
The present study investigated whether bevacizumab (BV) is associated with postoperative wound complications (PWCs). We retrospectively analyzed patients undergoing surgery for liver metastases of colorectal cancer at our Institution. Patients were divided into 3 groups according to the preoperative treatment: che mo therapy with BV (group A), chemotherapy without BV (group B) and no chemotherapy (group C). Between February 2003 and September 2012, 297 patients underwent 373 surgeries. Groups A, B and C consisted of 23, 62 and 288 patients, respectively. PWCs occurred in 29 patients (7.8%). In multivariate analysis, there were no differences in PWCs among the groups (C vs. B:P=0.739; C vs. A: P=0.110). Conversely, lower serum albumin levels (<3.5 g/dl vs. ≥ 3.5 g/dl: p=0.030) and synchronous colorectal resection (no vs. yes; p<0.001) remained significant risk factors of developing PWCs. Chemotherapy with or without BV did not influence the risk of PWCs.